Institutional members access full text with Ovid®

Share this article on:

Single-institution Experience of SBRT for Lung Metastases in Sarcoma Patients

Soyfer, Viacheslav MD; Corn, Benjamin W. MD; Shtraus, Natan MSc; Honig, Nir BSc; Meir, Yaron BSc; Kollender, Jehuda MD; Merimsky, Ofer MD

American Journal of Clinical Oncology: February 2017 - Volume 40 - Issue 1 - p 83–85
doi: 10.1097/COC.0000000000000103
Original Articles: Soft Tissue

Objectives: Lung metastasectomy is regarded as the standard procedure for improving the prognosis of patients with metastatic sarcoma. Few reports are available in the literature describing the value of stereotactic body radiation therapy (SBRT) of lung metastases from primary sarcoma as an alternative to surgical treatment. We therefore sought to expand the evidence base for this modality.

Materials and Methods: Twenty-two patients with metastatic sarcoma to lung were treated by SBRT. The retrospective analysis of overall survival, toxicity, and local control of 53 treated lesions is presented in the study. Lung lesions were grouped into 2 categories for follow-up: <10 mm or ≥10 mm diameter.

Results: Of 34 lesions <10 mm, 24 achieved complete response, 3 partial response, and 7 stable disease. The results of 18 lesions measuring >10 mm were as follows: 5 complete response, 5 progressive disease, and 8 stable disease. No progressive disease of all SBRT treated lesions was found at a median follow-up of 95 months (SD 32). Five-year overall survival of the entire group was 62% from the time of diagnosis and 50% from start of treatment. The treatment was well tolerated with minimal, mainly skin toxicity.

Conclusion: SBRT is an effective tool that might be used as an alternative to operative treatment of lung metastases in sarcoma patients

Tel Aviv Medical Center, Tel Aviv University, Tel Aviv, Israel

The authors declare no conflicts of interest.

Reprints: Viacheslav Soyfer, MD, Tel Aviv Medical Center, Tel Aviv University, 6Weizman St, Tel Aviv 64239, Israel. E-mail:

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.